These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36210072)

  • 1. Long non-coding RNA in Non-alcoholic fatty liver disease.
    Rohilla S; Kaur S; Puria R
    Adv Clin Chem; 2022; 110():1-35. PubMed ID: 36210072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis.
    Atanasovska B; Rensen SS; Marsman G; Shiri-Sverdlov R; Withoff S; Kuipers F; Wijmenga C; van de Sluis B; Fu J
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review.
    Shi N; Sun K; Tang H; Mao J
    J Clin Lab Anal; 2023 Jun; 37(11-12):e24943. PubMed ID: 37435630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease.
    Rohilla S; Awasthi A; Kaur S; Puria R
    Life Sci; 2021 Jan; 264():118560. PubMed ID: 33045214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review.
    Zeng Q; Liu CH; Wu D; Jiang W; Zhang N; Tang H
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNAs as modulators and therapeutic targets in non-alcoholic fatty liver disease (NAFLD).
    Tao Q; Xie J; Wu Y; Jin Y
    Gastroenterol Hepatol; 2024 May; 47(5):506-516. PubMed ID: 37806343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
    Ma TT; Huang C; Ni Y; Yang Y; Li J
    Cell Physiol Biochem; 2018; 51(2):871-885. PubMed ID: 30466110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.
    Sookoian S; Rohr C; Salatino A; Dopazo H; Fernandez Gianotti T; Castaño GO; Pirola CJ
    Oncotarget; 2017 Apr; 8(14):22917-22926. PubMed ID: 28206970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulatory
    Albadawy R; Agwa SHA; Khairy E; Saad M; El Touchy N; Othman M; El Kassas M; Matboli M
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.
    Khalifa O; Errafii K; Al-Akl NS; Arredouani A
    Dis Markers; 2020; 2020():8822859. PubMed ID: 33133304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
    Drescher HK; Weiskirchen S; Weiskirchen R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
    Gunn NT; Shiffman ML
    Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis.
    Chen Y; Huang H; Xu C; Yu C; Li Y
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28275212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment.
    De Vincentis A; Rahmani Z; Muley M; Vespasiani-Gentilucci U; Ruggiero S; Zamani P; Jamialahmadi T; Sahebkar A
    Drug Discov Today; 2020 Jul; 25(7):1277-1286. PubMed ID: 32439605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.